Association of angiogenesis and disease outcome in nodePositive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: A cancer and leukemia group B correlative science study from protocols 8541/8869

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 732-742

  Guidi, Anthony J ^a   Berry, Donald A ^a   Broadwater, Gloria ^a   Helmchen, Birgit ^a   Bleiweiss, Ira J ^a   Budman, Daniel R ^a   Henderson, I Craig ^a   Norton, Larry ^a   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; TAMOXIFEN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IMMUNOHISTOCHEMISTRY; LYMPH NODES; NEOVASCULARIZATION, PATHOLOGIC; OBSERVER VARIATION; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 0036467650     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.732     Document Type: Article

References (59)

1. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma
2. Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma
3. Microvessel quantitation and prognosis in invasive breast carcinoma
4. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
5. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
6. Tumor angiogenesis in node-negative breast carcinomas: Relationship with epidermal growth factor receptor, estrogen receptor, and survival
7. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool
8. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
9. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients
10. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node-negative patients
11. Behavior of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen
12. Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy
13. The prognostic significance of tumor angiogenesis in Taiwanese patients with invasive ductal breast carcinomas
14. Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis
15. Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy
16. Is the relationship between angiogenesis and metastasis in breast cancer real?
17. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer
18. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
19. Prognostic significance of microvessel density in lymph node negative breast carcinoma
20. Assessment of angiogenesis in breast carcinoma: An important factor in prognosis?
21. Association of angiogenesis in lymph node metastases with outcome of breast cancer
22. Assessment of tumor angiogenesis in invasive breast carcinomas: Absence of correlation with prognosis and pathological factors
23. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers
24. Dose and dose intensity trial of adjuvant chemotherapy for stage II, node positive breast carcinoma: Initial results of CALGB 8541
25. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B
26. c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer
27. erbB2, p53, and adjuvant therapy interactions in node positive breast cancer
28. Loss of tumor marker immunostaining intensity on stored paraffin slides of breast cancer
29. Microvessel density and distribution in ductal carcinoma in situ of the breast
30. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast
31. Angiogenesis and breast cancer
32. Do we need prognostic factors in nodal-negative breast cancer? Arbiter
33. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
34. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients
35. Breast cancer prognostic factors: Evaluation guidelines
36. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG9114/NCIC MA-13
37. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
38. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy
39. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis
40. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer
41. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer
42. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target
43. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer
44. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma
45. Bcl- 2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line
46. p53 and vascularendothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
47. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation
48. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis
49. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients
50. Examining the technique of angiogenesis assessment in invasive breast cancer
51. More about: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
52. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
53. Vascular grading of angiogenesis: Prognostic significance in breast cancer
54. Breast carcinoma: Vascular density determined using CD 105 antibody correlates with tumor prognosis
55. Surrogate markers of tumoral angiogenesis
56. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer
57. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component LH 39
58. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies